<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0405200073
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OZERO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Etoricoxib
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40.999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3661]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pharco International pharmaceutical company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharco International pharmaceutical company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What is OZERO?</p><p>OZERO contains the active substance etoricoxib. OZERO is one of a group of medicines called selective COX-2 inhibitors. These belong to a family of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).</p><p>What is OZERO used for?</p><p>OZERO helps to reduce the pain and swelling (inflammation) in the joints and muscles of people 16 years of age and older with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout.</p><p>OZERO is also used for the short term treatment of moderate pain after dental surgery in people 16 years of age and older.</p><p>What is osteoarthritis?</p><p>Osteoarthritis is a disease of the joints. It results from the gradual breakdown of cartilage that cushions the ends of the bones. This causes swelling (inflammation), pain, tenderness, stiffness and disability.</p><p>What is rheumatoid arthritis?</p><p>Rheumatoid arthritis is a long term inflammatory disease of the joints. It causes pain, stiffness, swelling, and increasing loss of movement in the joints it affects. It may also cause inflammation in other areas of the body.</p><p>What is gout?</p><p>Gout is a disease of sudden, recurring attacks of very painful inflammation and redness in the joints. It is caused by deposits of mineral crystals in the joint.</p><p>What is ankylosing spondylitis?</p><p>Ankylosing spondylitis is an inflammatory disease of the spine and large joints.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take OZERO:</p><p>If you are allergic (hypersensitive) to etoricoxib or any of the other ingredients of this medicine (listed in section 7)</p><p>If you are allergic to non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors (see Possible Side Effects, section 5)</p><p>If you have a current stomach ulcer or bleeding in your stomach or intestines</p><p>If you have serious liver disease</p><p>If you have serious kidney disease</p><p>If you are or could be pregnant or are breast-feeding (see &lsquo;Pregnancy, breast feeding and fertility&rsquo;)</p><p>If you are under 16 years of age</p><p>If you have inflammatory bowel disease, such as Crohn&rsquo;s Disease, Ulcerative Colitis, or Colitis</p><p>If you have high blood pressure that has not been controlled by treatment (check with your doctor or nurse if you are not sure whether your blood pressure is adequately controlled)</p><p>If your doctor has diagnosed heart problems including heart failure (moderate or severe types), angina (chest pain)</p><p>If you have had a heart attack, bypass surgery, peripheral arterial disease (poor circulation in legs or feet due to narrow or blocked arteries)</p><p>If you have had any kind of stroke (including mini-stroke, transient ischaemic attack or TIA). Etoricoxib may slightly increase your risk of heart attack and stroke and this is why it should not be used in those who have already had heart problems or stroke.</p><p>If you think any of these are relevant to you, do not take the tablets until you have consulted your doctor.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking OZERO if:</p><p>You have a history of stomach bleeding or ulcers.</p><p>You are dehydrated, for example by a prolonged bout of vomiting or diarrhoea.</p><p>You have swelling due to fluid retention.</p><p>You have a history of heart failure, or any other form of heart disease.</p><p>You have a history of high blood pressure. OZERO can increase blood pressure in some people, especially in high doses, and your doctor will want to check your blood pressure from time to time.</p><p>You have any history of liver or kidney disease.</p><p>You are being treated for an infection. OZERO can mask or hide a fever, which is a sign of infection.</p><p>You have diabetes, high cholesterol, or are a smoker. These can increase your risk of heart disease.</p><p>You are a woman trying to become pregnant.</p><p>You are over 65 years of age.</p><p>If you are not sure if any of the above apply to you, talk to your doctor before taking OZERO to see if this medicine is suitable for you.</p><p>OZERO works equally well in older and younger adult patients. If you are over 65 years of age, your doctor will want to appropriately keep a check on you. No dosage adjustment is necessary for patients over 65 years of age.</p><p>Children and adolescents</p><p>Do not give this medicine to children and adolescents under 16 years of age.</p><p>&nbsp;</p><p>Other medicines and OZERO</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>In particular if you are taking any of the following medicines, your doctor may want to monitor you to check that your medicines are working properly, once you start taking OZERO:</p><p>Medicines that thin your blood (anticoagulants), such as warfarin</p><p>Rifampicin (an antibiotic)</p><p>Methotrexate (a drug used for suppressing the immune system, and often used in rheumatoid arthritis)</p><p>Ciclosporin or tacrolimus (drugs used for suppressing the immune system)</p><p>Lithium (a medicine used to treat some types of depression)</p><p>Medicines used to help control high blood pressure and heart failure called ace inhibitors and angiotensin receptor blockers, examples include enalapril and ramipril, and losartan and valsartan</p><p>Diuretics (water tablets)</p><p>Digoxin (a medicine for heart failure and irregular heart rhythm)</p><p>Minoxidil (a drug used to treat high blood pressure)</p><p>Salbutamol tablets or oral solution (a medicine for asthma)</p><p>Birth control pills (the combination may increase your risk of side effects)</p><p>Hormone replacement therapy (the combination may increase your risk of side effects)</p><p>Aspirin, the risk of stomach ulcers is greater if you take OZERO with aspirin.</p><p>Aspirin for prevention of heart attacks or stroke:</p><p>OZERO can be taken with low-dose aspirin. If you are currently taking low-dose aspirin to prevent heart attacks or stroke, you should not stop taking aspirin until you talk to your doctor</p><p>Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs):</p><p>Do not take high dose aspirin or other anti-inflammatory medicines while taking OZERO.</p><p>OZERO with food and drink</p><p>The onset of the effect of OZERO may be faster when taken without food.</p><p>Pregnancy, breast-feeding and fertility</p><p>Pregnancy</p><p>OZERO tablets must not be taken during pregnancy. If you are pregnant or think you could be pregnant, or if you are planning to become pregnant, do not take the tablets. If you become pregnant, stop taking the tablets and consult your doctor. Consult your doctor if you are unsure or need more advice.</p><p>Breast-feeding</p><p>It is not known if OZERO is excreted in human milk. If you are breast-feeding, or planning to breast-feed, consult your doctor before taking OZERO. If you are using OZERO, you must not breast-feed.</p><p>Fertility</p><p>OZERO is not recommended in women attempting to become pregnant.</p><p>Driving and using machines</p><p>Dizziness and sleepiness have been reported in some patients taking OZERO.</p><p>Do not drive if you experience dizziness or sleepiness.</p><p>Do not use any tools or machines if you experience dizziness or sleepiness.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Do not take more than the recommended dose for your condition. Your doctor will want to discuss your treatment from time to time. It is important that you use the lowest dose that controls your pain and you should not take OZERO for longer than necessary. This is because the risk of heart attacks and strokes might increase after prolonged treatment, especially with high doses.</p><p>There are different strengths available for this medicinal product and depending on your disease your doctor will prescribe the tablet strength that is appropriate for you.</p><p>The recommended dose is:</p><p>Osteoarthritis</p><p>The recommended dose is 30 mg once a day, increase to a maximum of 60 mg once a day if needed.</p><p>Rheumatoid arthritis</p><p>The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p>&nbsp;</p><p>Ankylosing spondylitis</p><p>The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p>People with liver problems</p><p>If you have mild liver disease, you should not take more than 60 mg a day.</p><p>If you have moderate liver disease, you should not take more than 30 mg a day.</p><p>Use in children and adolescents</p><p>OZERO tablets should not be taken by children or adolescents under 16 years of age.</p><p>Elderly</p><p>No dose adjustment is necessary for elderly patients. As with other medicines, caution should be exercised in elderly patients.</p><p>Method of administration</p><p>OZERO is for oral use. Take the tablets once a day. OZERO can be taken with or without food.</p><p>If you take more OZERO than you should</p><p>You should never take more tablets than the doctor recommends. If you do take too many OZERO tablets, you should seek medical attention immediately.</p><p>If you forget to take OZERO</p><p>It is important to take OZERO as your doctor has prescribed. If you miss a dose, just resume your usual schedule the following day. Do not take a double dose to make up for the forgotten tablet.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you develop any of these signs you should stop OZERO and talk to your doctor immediately (see What you need to know before you take OZERO section 2):</p><p>&nbsp;</p><p>Shortness of breath, chest pains, or ankle swelling appear or if they get worse</p><p>Yellowing of the skin and eyes (jaundice) &ndash; these are signs of liver problems</p><p>Severe or continual stomach pain or your stools become black</p><p>An allergic reaction- which can include skin problems such as ulcers or blistering, or swelling of the face, lips, tongue, or throat which may cause difficulty in breathing</p><p>The frequency of possible side effects listed below is defined using the following convention:</p><p>Very common (affects more than 1 user in 10)</p><p>Common (affects 1 to 10 users in 100)</p><p>Uncommon (affects 1 to 10 users in 1,000)</p><p>Rare (affects 1 to 10 users in 10,000)</p><p>Very rare (affects less than 1 user in 10,000)</p><p>The following side effects can occur during treatment with OZERO:</p><p>Very common</p><p>Stomach pain</p><p>Common</p><p>Dry socket (inflammation and pain after a tooth extraction)</p><p>Swelling of the legs and/or feet due to fluid retention (oedema)</p><p>Dizziness, headache</p><p>Palpitations (fast or irregular heartbeat), irregular heart rhythm (arrhythmia)</p><p>Increased blood pressure</p><p>Wheezing or shortness of breath (bronchospasms)</p><p>Constipation, wind (excessive gas), gastritis (inflammation of the lining of the stomach), heartburn, diarrhea, indigestion (dyspepsia)/stomach discomfort, nausea, being sick (vomiting), inflammation of the esophagus, mouth ulcers</p><p>Changes in blood tests related to your liver</p><p>Bruising</p><p>Weakness and fatigue, flu-like illness</p><p>Uncommon</p><p>Gastroenteritis (inflammation of the gastrointestinal tract that involves both the stomach and small intestine/stomach flu), upper respiratory infection, urinary tract infection</p><p>Changes in laboratory values (decreased number of red blood cells, decreased number of white blood cells, platelets decreased)</p><p>Hypersensitivity (an allergic reaction including hives which may be serious enough to require immediate medical attention)</p><p>Appetite increases or decreases, weight gain</p><p>Anxiety, depression, decreases in mental sharpness; seeing, feeling or hearing things that are not there (hallucinations)</p><p>Taste alteration, inability to sleep, numbness or tingling, sleepiness</p><p>Blurred vision, eye irritation and redness</p><p>Ringing in the ears, vertigo (sensation of spinning while remaining still)</p><p>Abnormal heart rhythm (atrial fibrillation), fast heart rate, heart failure, feeling of tightness, pressure or heaviness in the chest (angina pectoris), heart attack</p><p>Flushing, stroke, mini-stroke (transient ischaemic attack), severe increase in blood pressure. Inflammation of the blood vessels</p><p>Cough, breathlessness, nose bleed</p><p>Stomach or bowel bloating, changes in your bowel habits, dry mouth, stomach ulcer, inflammation of the stomach lining that can become serious and may lead to bleeding, irritable bowel syndrome, inflammation of the pancreas</p><p>Swelling of the face, skin rash or itchy skin, redness of the skin</p><p>Muscle cramp/spasm, muscle pain/stiffness</p><p>High levels of potassium in your blood, changes in blood or urine tests relating to your kidney, serious kidney problems</p><p>Chest pain</p><p>Rare</p><p>Angioedema (an allergic reaction with swelling of the face, lips, tongue and/or throat which may cause difficulty in breathing or swallowing, which may be serious enough to require immediate medical attention)/anaphylactic/anaphylactoid reactions including shock (a serious allergic reaction that requires immediate medical attention)</p><p>Confusion, restlessness</p><p>Liver problems (hepatitis)</p><p>Low blood levels of sodium</p><p>Liver failure, yellowing of the skin and/or eyes (jaundice)</p><p>Severe skin reactions</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store below 30&deg;C.</p><p>Do not use OZERO. After the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What OZERO contains:</p><p>&bull; The active substance is Etoricoxib</p><p>&bull; The other ingredients are:</p><p>Calcium hydrogen phosphate anhydrous, Microcrystalline cellulose (Avicel PH 112), Croscarmellose sod, Colloidal silicon dioxide (Aerosil200), Magnesium Stearate, Opadry II green or Opadry II White</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • OZERO 60 mg is Pale green biconvex Shaped Film coated tablet embossed with SJ 12E on one side. 
• OZERO 90 mg is white biconvex Shaped Film coated tablet embossed with SJ 13C on one side.
• OZERO 120 mg is Pale green biconvex Shaped Film coated tablet embossed with SJ 15C on one side. 

OZERO 60 mg is provided in Alu/Alu blister 
Packs contain 30 film coated tablet

OZERO 90 mg is provided in Alu/Alu blister 
Packs contain 30 film coated tablet

OZERO 120 mg is provided in Alu/Alu blister 
Packs contain 7 film coated tablet

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharco International pharmaceutical company- Al Madina Almonawara, Saudi Arabia</p><p>TEL: +966 112349763</p><p>&nbsp;</p><p>Manufacturer</p><p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited</p><p>Jeddah &ndash; Saudi Arabia</p><p>&nbsp;</p><p>For any information about OZERO, please contact:</p><p>Pharco International pharmaceutical company- Al Madina Almonawara, Saudi Arabia</p><p>Tel: +966 112349763</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {October/2019}; version number {00}
--To report any side effect (s)
• Saudi Arabia :
− National Pharmacovigilance Center (NPC)
O Fax: +966-11-205-7662 
O Call NPC at +966-112038222, Exts: 2317-2356-2353-2354-2334-2340
O Toll free phone: 8002490000
O E-mail: npc.drug@sfda.gov.sa
O Website: www.sfda.gov.sa/npc

• Other GCC states /other countries 
-Please contact the relevant competent authority.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ما هو أوزيرو؟</p><p dir="RTL">يحتوي أوزيرو على المادة الفعّالة اتوريكوكسيب. أوزيرو هو واحد من مجموعة أدوية تُسَمَّى مثبطات الأكسدة الحلقية-2 الانتقائية. تنتمي هذه الأدوية إلى فئة تُسمى مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">ماهي دواعي استعماله</p><p dir="RTL">يُساعد أوزيرو على الحد من الألم والتورُّم (الالتهاب) في مفاصل وعضلات الأشخاص ممن يبلغون من العُمْر 16 عامًا فأكثر والمصابين بالتهاب المفاصل والتهاب المفاصل الروماتويدي والتهاب الفقار اللاصق ومرض النقرس.</p><p dir="RTL">يُستَخدَم أوزيرو أيضًا للعلاج قصير الأمد للألم المتوسط بعد جراحة الأسنان في الأشخاص ممن يبلغون من العُمْر 16 عامًا فأكثر.</p><p dir="RTL">ما هو مرض التهاب المفاصل؟</p><p dir="RTL">مرض التهاب المفاصل هو مرض يُصيب المفاصل، وينتج عن التحلُّل التَّدريجي للغضروف الذي يعمل كبطانة لنهايات العظام، مما يُسبب تورُّمًا (التهابًا) وألمًا وأوجاعًا وتصلبًا وإعاقةً.</p><p dir="RTL">ما هو التهاب المفاصل الروماتويدي؟</p><p dir="RTL">التهاب المفاصل الروماتويدي هو مرض التهابي طويل الأمد بالمفاصل. يُسبب هذا المرض ألمًا وتصلبًا وتورُّمًا وتزايُدًا في فقدان الحركة في المفاصل التي يصيبها المرض. قد يُسبب أيضًا التهابًا في مناطق أخرى بالجسم.</p><p dir="RTL">ما هو مرض النقرس؟</p><p dir="RTL">النقرس هو مرض يحدث في شكل نوبات مفاجئة ومتكررة من الالتهاب المؤلم للغاية والاحمرار في المفاصل، وينجم عن ترسُّبات من البلورات المعدنية في المفصل.</p><p dir="RTL">ما هو التهاب الفقار اللاصق؟</p><p dir="RTL">التهاب الفقار اللاصق هو مرض التهابي بالعمود الفقري والمفاصل الكبيرة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول أوزيرو في الحالات الآتية:</p><p dir="RTL">إذا كنت تعاني من الحساسية (الحساسية المفرطة) تجاه اتوريكوكسيب أو أيٍّ من مكونات هذا الدَّواء (المُدرَجة في قسم 7).</p><p dir="RTL">إذا كنت مصابًا بحساسية تجاه مضادات الالتهاب غير الستيرويدية، بما في ذلك الأسبرين ومثبطات الأكسدة الحلقية-2 (انظر قسم 5: &quot;الاعراض الجانبية ).</p><p dir="RTL">إذا كنت مُصابًا حاليًا بقرحة في المعدة أو نزيف في المعدة أو الأمعاء.</p><p dir="RTL">إذا كان لديك مرض خطير بالكبد.</p><p dir="RTL">إذا كان لديك مرض خطير بالكُلى.</p><p dir="RTL">إذا كنتِ حاملًا أو قد تصبحين حاملًا أو كنتِ مُرضعًا (انظري: &quot;الحَمْل والرضاعة الطبيعية والخصوبة&quot;).</p><p dir="RTL">إذا كنت بعمر أقل من 16 عامًا.</p><p dir="RTL">إذا كنت مصابًا بمرض التهابي بالأمعاء، مثل: مرض كرون أو التهاب القولون التَّقرحي أو التهاب القولون.</p><p dir="RTL">إذا كنت مصابًا بارتفاع ضغط الدَّم الذي لم يتم ضبطه عن طريق العلاج (راجع مع طبيبك أو الممرضـ(ة) إذا لم تكن متأكدًا مما إذا كان ضغط الدَّم لديك يتم ضبطه بشكل كافٍ أم لا).</p><p dir="RTL">إذا قام طبيبك بتشخيص إصابتك بمشاكل في القلب بما في ذلك فشل القلب (من النوع المعتدل أو الشديد)، أو ذبحة صدرية (ألم بالصدر).</p><p dir="RTL">إذا كنت قد أُصِبت بنوبة قلبية، أو خضعت لجراحة مَجازَة، أو مرض بشريان طرفي (ضعف الدَّورة الدَّموية في الساقين أو القدمين نتيجة تضيُّق أو انسداد الشرايين).</p><p dir="RTL">إذا كنت قد أُصِبت بأي نوع من السكتة الدماغية (بما في ذلك سكتة دماغية صغرى أو نوبة إقفارية عابرة). قد يُزيد اتوريكوكسيب بشكل طفيف من نسبة خطورة الإصابة بنوبة قلبية وسكتة دماغية؛ ولذا يجب عدم استخدامه في أولئك الذين أُصيبوا بالفعل بمشاكل قلبية أو سكتة دماغية.</p><p dir="RTL">إذا اعتقدت أن أيًّا من هذه الحالات ذو صلة بك، فلا تتناول الأقراص حتى تستشير طبيبك.</p><p dir="RTL">التَّحذيرات والاحتياطات</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل أوزيرو في الحالات التَّالية:</p><p dir="RTL">إذا كان لديك تاريخ مرضي من الإصابة بنزيف المعدة أو القرح.</p><p dir="RTL">إذا كنت مصابًا بجفاف ناجم عن، على سبيل المثال، نوبة طويلة من القيء أو الإسهال.</p><p dir="RTL">إذا كنت مصابًا بتورُّم نتيجة احتباس السوائل.</p><p dir="RTL">إذا كان لديك تاريخ مرضي من فشل القلب، أو أي شكل آخر من أمراض القلب.</p><p dir="RTL">إذا كان لديك تاريخ مرضي من الإصابة بارتفاع ضغط الدَّم. يُمكِن أن يرفع أوزيرو ضغط الدَّم لدى بعض الأشخاص، لا سيما عند تناوُله بجرعات مرتفعة، وسيرغب طبيبك في فحص ضغط الدَّم لديك من حين لآخر.</p><p dir="RTL">إذا كان لديك أي تاريخ مرضي من الإصابة بمرض بالكبد أو الكُلى.</p><p dir="RTL">إذا كنت تتلقى علاجًا لعدوى ما. يُمكِن أن يحجب أوزيرو أو يخفي إصابتك بحُمى، والتي تُعَد إحدى علامات العدوى.</p><p dir="RTL">إذا كنت مصابًا بمرض السُّكَّري أو ارتفاع نسبة الكوليسترول أو كنت مدخنًا. يُمكن أن تزيد هذه الحالات من خطورة إصابتك بمرض بالقلب.</p><p dir="RTL">إذا كنتِ سيدة تحاولين أن تصبحي حاملًا.</p><p dir="RTL">إذا كنت أكبر من 65 عامًا.</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ينطبق عليك أيٌّ مما سبق، فيُرجى التَّحدث إلى طبيبك أو الصيدلي قبل تناوُل أوزيرو؛ لمعرفة ما إذا كان هذا الدَّواء مناسبًا لك أم لا.</p><p dir="RTL">يعمل أوزيرو بشكل جيد في المرضى من كبار السن والأصغر سنًّا على حد سواء. إذا كان عمرك يزيد على 65 عامًا، قد يحتاج طبيبك إلى إجراء فحوصات مُنتظمة لك. لا يستلزم الأمر تعديل الجرعة للمرضى ممن تزيد أعمارهم عن 65 عامًا.</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">لا يعطى هذا الدَّواء للأطفال والمراهقين الأقل من 16 سنة.</p><p dir="RTL">تناوُل أوزيرو مع أدوية أخرى</p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى، بما في ذلك أية أدوية أخرى حصلت عليها دون وصفة طبية.</p><p dir="RTL">إذا كنت تتناول أيًّا من الأدوية التَّالية على وجه الخصوص، فقد يرغب طبيبك في مراقبتك؛ للتَّأكد من عمل الأدوية التي تتناولها بشكل صحيح، بمجرد بدء تناوُلك لأوزيرو:</p><p dir="RTL">الأدوية التي تقوم بتسييل دمك (مضادات التجلُّط)، مثل: وارفارين.</p><p dir="RTL">ريفامبيسين (مضاد حيوي).</p><p dir="RTL">ميثوتريكسات (عقار يُستَخدَم لتثبيط الجهاز المناعي، وغالبًا يُستَخدَم في علاج التهاب المفاصل الروماتويدي).</p><p dir="RTL">سيكلوسبورين أو تاكروليموس (عقاقير تُستَخدَم لتثبيط الجهاز المناعي).</p><p dir="RTL">الليثيوم (دواء يُستَخدَم لعلاج بعض الأنواع من الاكتئاب).</p><p dir="RTL">الأدوية التي تُستَخدَم لضبط ارتفاع ضغط الدَّم وفشل القلب والتي تُدعى مُثبطات إنزيم تحويل الأنجيوتنسين وحاصرات مستقبلات الأنجيوتنسين، تتضمن الأمثلة: إنالابريل وراميبريل ولوسارتان وفالسارتان.</p><p dir="RTL">مدرات البول (أقراص الماء).</p><p dir="RTL">ديجوكسِين (دواء لعلاج الفشل القلبي وعدم انتظام النَّظْم القلبي).</p><p dir="RTL">مينوكسيديل (يُستخدم لعلاج ارتفاع ضغط الدَّم).</p><p dir="RTL">سالبوتامول أقراص أو محلول فموي (دواء لعلاج الربو).</p><p dir="RTL">حبوب منع الحمل (قد تُزيد التَّركيبة من نسبة خطورة إصابتك باعراض&nbsp; جانبية).</p><p dir="RTL">العلاج بالهرمونات التَّعويضية (قد تُزيد التركيبة من نسبة خطورة إصابتك باعراض جانبية).</p><p dir="RTL">الأسبرين، تكون نسبة خطورة الإصابة بقُرَح في المعدة أكبر إذا تناولت أوزيرو مع الأسبرين.</p><p dir="RTL">الأسبرين للوقاية من النوبات القلبية أو السكتة الدماغية:</p><p dir="RTL">يُمكِن تناوُل أوزيرو مع جرعة منخفضة من الأسبرين. إذا كنت تتناول حاليًا جرعة منخفضة من الأسبرين للوقاية من النوبات القلبية أو السكتة الدماغية، فيجب ألا تتوقف عن تناوُل الأسبرين حتى تتحدَّث إلى طبيبك.</p><p dir="RTL">الأسبرين ومضادات الالتهاب غير الستيرويدية الأخرى:</p><p dir="RTL">لا تتناول جرعة مرتفعة من الأسبرين أو الأدوية الأخرى المضادة للالتهاب أثناء تناوُل أوزيرو.</p><p dir="RTL">تناوُل أوزيرو مع الطعام والشراب</p><p dir="RTL">قد يكون ظهور تأثير لأوزيرو أسرع عند تناوُله بدون الطعام.</p><p>الحمل والرَّضاعة الطبيعية والخصوبة</p><p>&nbsp;</p><p dir="RTL">الحمل</p><p dir="RTL">لا تتناولي أقراص أوزيرو خلال فترة الحمل. إذا كنتِ حاملًا أو تعتقدين أنكِ قد تكونين حاملًا، أو إذا كنتِ تخططين للحمل، فلا تتناولي الأقراص. إذا أصبحتِ حاملًا، فتوقفي عن تناوُل الأقراص واستشيري طبيبك. استشيري طبيبك إذا كنتِ غير متأكدة من كيفية التَّناول أو تحتاجين إلى المزيد من المشورة.</p><p dir="RTL">الرَّضاعة الطبيعية</p><p dir="RTL">من غير المعروف ما إذا كان يتم إفراز أوزيرو في لبن الأم أم لا. يجب عليك استشارة طبيبك قبل تناوُل أوزيرو إذا كنتِ مرضعًا أو تنوين الإرضاع. إذا كنتِ تستخدمين أوزيرو، فلا تمارسي الرضاعة الطبيعية.</p><p dir="RTL">الخصوبة</p><p dir="RTL">لا يُوصى باستخدام أوزيرو في السيدات اللاتي تحاولن الحَمْل.</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">تم الإبلاغ عن حدوث دوخة ونُعاس لدى بعض المرضى ممن يتناولون أوزيرو.</p><p dir="RTL">لا تمارس القيادة إذا تعرَّضت لدوخة أو نُعاس.</p><p>لا تستخدم أي أدوات أو آلات إذا تعرَّضت لدوخة أو نُعاس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يجب مراجعة الطبيب أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التَّناوُل.</p><p dir="RTL">لا تتناول أكثر من الجرعة الموصى بها لحالتك. سيرغب طبيبك في مناقشة علاجك من حين إلى آخر. فمن المهم استخدام أدنى جُرعة تضبط الألم لديك، ويجب عدم استخدام أوزيرو لوقت أطول من اللازم. هذا لأن نسبة خطورة الإصابة بنوبات قلبية وسكتات دماغية قد ترتفع بعد العلاج لفترة طويلة، خاصةً بجرعات مرتفعة.</p><p dir="RTL">هناك تركيزات مختلفة متاحة لهذا المُنتَج الدَّوائي ووفقًا لمرضك، وسيصف لك طبيبك تركيز القرص المناسب لك.</p><p dir="RTL">الجُرعة المُوصى بها هي:</p><p dir="RTL">التهاب المفاصل</p><p dir="RTL">الجرعة المُوصى بها هي 30 ملج مرة واحدة في اليوم، وتزيد إلى حد أقصى 60 ملج مرة واحدة في اليوم إذا لزم الأمر.</p><p dir="RTL">التهاب المفاصل الروماتويدي</p><p dir="RTL">الجرعة الموصى بها هي 60 ملغ مرة واحدة يوميا. في بعض المرضى الذين لم يتعافوا بشكل غير كاف من الأعراض. زيادة الجرعة الى 90 ملغ مرة واحدة يوميا قد يزيد من الفعالية. بمجرد استقرار المريض سريريا، قد يكون من المناسب خفض الجرعة تدريجيا إلى 60 ملغ مرة واحدة يوميا. في حالة عدم وجود زيادة في الفوائد العلاجية، ينبغي النظر في الخيارات العلاجية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب الفقار اللاصق</p><p dir="RTL">الجرعة الموصى بها هي 60 ملغ مرة واحدة يوميا. في بعض المرضى الذين لم يتعافوا بشكل غير كاف من الأعراض. زيادة الجرعة الى 90 ملغ مرة واحدة يوميا قد يزيد من الفعالية. بمجرد استقرار المريض سريريا، قد يكون من المناسب خفض الجرعة تدريجيا إلى 60 ملغ مرة واحدة يوميا. في حالة عدم وجود زيادة في الفوائد العلاجية، ينبغي النظر في الخيارات العلاجية الأخرى.</p><p dir="RTL">حالات الألم الحاد</p><p dir="RTL">يجب استخدام اتوريكوكسيب فقط خلال فترة الألم الحاد.</p><p dir="RTL">مرض النقرس</p><p dir="RTL">الجرعة المُوصى بها هي 120 ملج مرة واحدة في اليوم، ويجب استخدامها فقط خلال فترة الألم الحاد، وتقتصر على حد أقصى 8 أيام من العلاج.</p><p dir="RTL">الألم التَّالي للخضوع لعملية جراحية في الأسنان</p><p dir="RTL">الجرعة الموصى بها هي 90 ملج مرة واحدة يوميًّا، وتقتصر على حد أقصى 3 أيام من العلاج.</p><p dir="RTL">الأشخاص المصابون بمشاكل في الكبد</p><p dir="RTL">إذا أُصِبت بمرض خفيف في الكبد، فيجب ألا تتناول أكثر من 60 ملج في اليوم.</p><p dir="RTL">إذا أُصِبت بمرض معتدل في الكبد، فيجب ألا تتناول أكثر من 30 ملج في اليوم.&nbsp;</p><p dir="RTL">الاستعمال في الأطفال والمراهقين</p><p dir="RTL">يجب ألا يتم تناوُل أوزيرو من قبل الأطفال والمراهقين ممن تقل أعمارهم عن 16 سنة.</p><p dir="RTL">المرضى من كبار السن</p><p dir="RTL">لا يستلزم الأمر تعديل الجرعة في المرضى من كبار السن. كما هو الحال مع الأدوية الأخرى، يجب توخي الحذر في المرضى من كبار السن.</p><p dir="RTL">طريقة التَّناوُل</p><p dir="RTL">أوزيرو معد للتناول عن طريق الفم فقط. تناول الأقراص مرة واحدة في اليوم. يمكن تناول أوزيرو مع الطعام أو بدونه.</p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من أوزيرو</p><p dir="RTL">يجب ألا تتناول كمية أقراص أكثر من التي أوصاك بها طبيبك. إذا تناولت بالفعل كمية كبيرة للغاية&nbsp; من أقراص أوزيرو، فيجب أن تطلب العناية الطبية فورًا.</p><p dir="RTL">إذانسيت تناوُل أوزيرو</p><p dir="RTL">من المهم أن تتناول أوزيرو طبقًا لتعليمات الطبيب. إذا نسيت تناوُل جرعة، فكل ما عليك فعله هو أن تستمر في تناوُله في اليوم التَّالي. لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء اعراض&nbsp; جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">إذا أُصِبت بأي من هذه العلامات فيجب أن تتوقف عن تناوُل أوزيرو، وأن تتحدَّث إلى طبيبك فورًا (انظر قسم 2: &quot;ما الذي تحتاج إلى معرفته قبل القيام بتناوُل أوزيرو&quot;)؟:</p><p dir="RTL">ضيق النفس، آلام في الصدر، أو ظهور تورُّم في الكاحل أو في حال تفاقمه.</p><p dir="RTL">اصفرار الجلد والعينين (يرقان) - تُعَد هذه علامات على وجود مشاكل بالكبد.</p><p dir="RTL">ألم شديد أو مستمر في المعدة أو براز أسود.</p><p dir="RTL">تفاعل حساسية - يُمكِن أن يشمل مشاكل بالجلد مثل: قرح أو نفطات، أو تورُّم الوجه أو الشفتين أو اللسان أو الحَلْق مما قد يُسَبب صعوبة في التَّنَفُّس.</p><p dir="RTL">يعرف معدَّل تكرار الاعراض الجانبية&nbsp; المدرجة أدناه باستخدام الاصطلاحات التَّالية:</p><p dir="RTL">شائعة جدًّا (تُؤثر على أكثر من مستخدم واحد من بين كل 10 مستخدمين)</p><p dir="RTL">شائعة (تُؤثر على مستخدم واحد إلى 10 مستخدمين من بين كل 100 مستخدم).</p><p dir="RTL">غير شائعة (تؤثر على مستخدم واحد إلى 10 مستخدمين من بين كل 1000 مستخدم).</p><p dir="RTL">نادرة (تُؤثر على مستخدم واحد إلى 10 مستخدمين من بين كل 10000 مستخدم).</p><p dir="RTL">نادرة جدًّا (تُؤثر على أقل من مستخدم واحد من بين كل 10000 مستخدم).</p><p dir="RTL">من الممكن حدوث الاعراض الجانبية التَّالية أثناء العلاج بأوزيرو:</p><p dir="RTL">شائعة جدًّا</p><p dir="RTL">ألم بالمعدة.</p><p dir="RTL">شائعة</p><p dir="RTL">سِنْخ جاف (التهاب وألم بعد خلع الأسنان).</p><p dir="RTL">تورُّم الساقين و/أو القدمين بسبب احتباس السوائل (وذمة).</p><p dir="RTL">دوخة، صداع.</p><p dir="RTL">خَفَقان (سرعة أو عدم انتظام ضربات القلب)، عدم انتظام النَّظْم القلبي (اضطرابات النَّظم القلبي).</p><p dir="RTL">ارتفاع ضغط الدَّم.</p><p dir="RTL">أزيز بالصدر أو ضيق النَّفس (تشنُّج قَصَبي).</p><p dir="RTL">إمساك، ريح (غازات مفرطة)، التهاب المعدة (التهاب بطانة المعدة)، حموضة، إسهال، عسر الهضم/ شعور غير مريح بالمعدة، غثيان، إعياء (قيء)، التهاب المريء، قرح بالفم.</p><p dir="RTL">تغيُّرات في نتائج اختبارات الدَّم المتعلقة بكبدك.</p><p dir="RTL">تكدُّم.</p><p dir="RTL">ضعف وإرهاق، مرض شبيه بالإنفلونزا.</p><p dir="RTL">غير شائعة</p><p dir="RTL">التهاب المعدة والأمعاء (التهاب الجهاز الهضمي الذي يشمل المعدة والأمعاء الدقيقة/ نزلة برد بالمعدة)، عدوى بالجهاز التَّنفسي العلوي، عدوى المسالك البولية.</p><p dir="RTL">تغيُّرات في القيم المعملية (انخفاض عدد خلايا الدَّم الحمراء، انخفاض عدد خلايا الدَّم البيضاء، انخفاض الصفائح الدَّموية).</p><p dir="RTL">فرط الحساسية (تفاعل حساسية يشمل: شرى [أرتكاريا] قد يكون خطيرًا بما يكفي ليستلزم عناية طبية فورية).</p><p dir="RTL">زيادة أو قلة الشهية، زيادة الوزن.</p><p dir="RTL">القلق، الاكتئاب، قلة التَّركيز، رؤية أو سماع أو الإحساس بأشياء غير موجودة (هلَاوِس).</p><p dir="RTL">تغيُّر المذاق، عدم القدرة على النوم، تنميل أو وخز، نُعاس.</p><p dir="RTL">عدم وضوح الرؤية، تهيُّج العين واحمرارها.</p><p dir="RTL">طنين بالأذن، دوار (إحساس بالدوران أثناء السكون).</p><p dir="RTL">اضطراب النَّظْم القلبي (الرجفان الأذيني)، تسارع معدَّل ضربات القلب، فشل القلب، الشعور بضيق أو ضغط أو ثقل بالصدر (ذبحة صدرية)، نوبة قلبية.</p><p dir="RTL">احمرار الجلد، سكتة دماغية، سكتة دماغية صُغرى (نوبة إقفارية عابرة)، ارتفاع شديد في ضغط الدَّم، التهاب الأوعية الدَّموية.</p><p dir="RTL">سُعال، عُسْر التَّنَفُّس، نزيف من الأنف.</p><p dir="RTL">انتفاخ المعدة أو الأمعاء، تغيُّرات في طبيعة عمل الأمعاء، جفاف الفم، قرحة بالمعدة، التهاب بطانة المعدة الذي قد يصبح خطيرًا وقد يُؤدي إلى النزيف، متلازمة القولون العصبي، التهاب البنكرياس.</p><p dir="RTL">تورُّم الوجه، طفح جلدي أو حكة بالجلد، احمرار الجلد.</p><p dir="RTL">تقلص/ تشنُّج عضلي، ألم/ تصلُّب عضلي.</p><p dir="RTL">ارتفاع مستويات البوتاسيوم في دمك، تغيُّرات في نتائج اختبارات الدَّم أو البول المتعلقة بالكُلى، مشاكل خطيرة بالكُلى.</p><p dir="RTL">ألم بالصدر.</p><p dir="RTL">نادرة</p><p dir="RTL">وذمة وعائية (تفاعل حساسية مصحوبة بتورُّم الوجه، والشفتين، واللسان و/أو الحَلْق قد يُسبب صعوبة في التَّنَفُّس أو البلع، مما قد يكون خطيرًا بما يكفي ليستلزم العناية الطبية الفورية)/ تفاعلات تأقية/ تأقانية تشمل: الصدمة (تفاعل حساسية خطير يتطلب العناية الطبية الفورية).</p><p dir="RTL">ارتباك، تململ.</p><p dir="RTL">مشاكل الكبد (التهاب الكبد).</p><p dir="RTL">انخفاض مستويات الصوديوم بالدَّم.</p><p dir="RTL">فشل كبدي، اصفرار الجلد و/أو العينين (يرقان).</p><p dir="RTL">التَّفاعلات الجلدية الشَّديدة.</p><p dir="RTL">إذا أصبح أيٌّ من الاعراض الجانبية خطيرًا، أو لاحظت اعراض جانبية غير المدرجة في هذه النَّشرة، يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن مُتناوَل الأطفال.</p><p dir="RTL">يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تَستخدِم أوزيرو بعد انتهاء تاريخ الصلاحية المدون على العبوة. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يجب عدم التَّخلص من الأدوية عن طريق مياه الصرف، أو مع المخلفات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد بحاجة إليها. ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات أوزيرو</p><p dir="RTL">&middot;المادة الفعَّالة هي اتوريكوكسيب.</p><p dir="RTL">&middot;المكونات الأخرى هي:</p><p dir="RTL">كالسيوم فوسفات الهيدروجين لا مائي، سليلوز دقيق التَّبلور (أفيسيل بي إتش 112)، كروس كارميلوز الصوديوم، ثاني أكسيد السيليكون الغروي (آيروسيل 200)، ستيرات الماغنسيوم، أوبادري أخضر اوأوبادري&nbsp; أبيض</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما هو شكل أوزيرو وما هي محتويات العبوة</p><p dir="RTL">&middot; أوزيرو 60 ملج هو أقراص مغلَّفة ذات لون أخضر باهت وشكل ثنائي التحدُّب منقوش على أحد جانبيها SJ 12E.</p><p dir="RTL">&middot; أوزيرو 90 ملج هو أقراص مغلَّفة بيضاء ثنائية التَّحدب منقوش على أحد جانبيها SJ 13C.</p><p dir="RTL">&middot; أوزيرو 120 ملج هو أقراص مغلَّفة ذات لون أخضر باهت ثنائية التحدُّب منقوش على أحد جانبيها SJ 15C.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفرأوزيرو 60 ملج في شرائط ألومنيوم/ ألومنيوم</p><p dir="RTL">تحتوي العبوة على 30 قرصًا مغلَّفًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفرأوزيرو 90 ملج في شرائط ألومنيوم/ ألومنيوم</p><p dir="RTL">تحتوي العبوة على 30 قرصًا مغلَّفًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفرأوزيرو 120 ملج في شرائط ألومنيوم/ ألومنيوم</p><p dir="RTL">تحتوي العبوة على 7 أقراص مغلَّفة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة أدوية فاركو انترناشونال - المدينة المنورة - المملكة العربية السعودية</p><p dir="RTL">هاتف رقم: 763 9 234 11 966+</p><p dir="RTL">جهة التَّصنيع</p><p dir="RTL">ساجا الصيدلانية</p><p dir="RTL">جدة &ndash; المملكة العربية السعودية</p><p dir="RTL">للحصول على أية معلومات حول هذا الدواء، يُرجى الاتصال بـ</p><p dir="RTL">شركة أدوية فاركو انترناشونال - المدينة المنورة - المملكة العربية السعودية</p><p>هاتف رقم: 763 9 234 11 966+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النَّشرة في {أكتوبر/ 2019}، إصدار رقم {00}
- للإبلاغ عن الاعراض الجانبية:
· المملكة العربية السعودية 
· المركز الوطني للتيقظ والسلامة الدوائية 
· فاكس: 112057662- 966+
· للاتصال بالادارة التنفيذية للتيقظ وادارة الأزمات . هاتف +966-11-20382222   تحويلة :2317-2356-2353-2354-2334-2340
· الهاتف المجاني : 8002490000
· البريد الإلكتروني: npc.drug@sfda.gov.sa
· الموقع الإلكتروني: www.sfda.gov.sa/npc

· دول الخليج الاخرى /الدول الاخرى :
· - الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة 

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OZERO 90 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OZERO 90mg film-coated tablets:
Each film-coated tablet o contains 90 mg Etoricoxib

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	OZERO 90 mg is white bioconvex Shaped Film coated tablet embossed with
SJ13C on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_39" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:-23.9pt;width:21.15pt;height:16.6pt;z-index:251634688;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>&nbsp;<p>OZERO is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis.</p></p><p>&nbsp;</p><p>OZERO is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery</p><p>The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3, 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_37" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:-23.75pt;width:21.15pt;height:16.6pt;z-index:251638784;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>&nbsp;</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><em>Posology</em></p><p>&nbsp;</p><p>As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).</p><p><em>Osteoarthritis</em></p><p>The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p><em>Rheumatoid arthritis</em></p><p><em>The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</em></p><p><em>Ankylosing spondylitis</em></p><p><em>&nbsp;</em></p><p><em>The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</em></p><p>For acute pain conditions, etoricoxib should be used only for the acute symptomatic period.</p><p><em>Acute gouty arthritis</em></p><p>The recommended dose is 120 mg once daily. In clinical trials for acute gouty</p><p>&nbsp;</p><p>arthritis, etoricoxib was given for 8 days.</p><p><em>Postoperative dental surgery pain</em></p><p><em>&nbsp;</em></p><p>The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require other postoperative analgesia in addition to OZERO during the three day treatment period.</p><p>Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore:</p><p>The dose for OA should not exceed 60 mg daily.</p><p>The dose for RA and ankylosing spondylitis should not exceed 90 mg daily.</p><p>The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days treatment.</p><p>The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a maximum of 3 days.</p><p>&nbsp;</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be exercised in elderly patients (see section 4.4).</p><p><em>Patients with hepatic impairment</em></p><p>Regardless of indication, in patients with mild hepatic dysfunction (Child-Pugh score 5-6) a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic dysfunction (Child-Pugh score 7-9), regardless of indication, the dose of 30 mg <em>once daily </em>should not be exceeded.</p><p>Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. There is no clinical experience in patients with severe hepatic dysfunction (Child-Pugh score &ge;10); therefore, its use is contra- indicated in these patients (see sections 4.3, 4.4 and 5.2).</p><p><em>Patients with renal impairment&nbsp;</em></p><p>No dosage adjustment is necessary for patients with creatinine clearance &ge;30</p><p>ml/min (see section 5.2). The use of etoricoxib in patients with creatinine clearance</p><p>&lt;30 ml/min is contra-indicated (see sections 4.3 and 4.4).</p><p><em>Paediatric population</em></p><p>Etoricoxib is contra-indicated in children and adolescents under 16 years of age (see section 4.3).</p><p>Method of administration</p><p>OZERO is administered orally and may be taken with or without food. The onset of the effect of the medicinal product may be faster when OZERO is administered without food. This should be considered when rapid symptomatic relief is needed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•	Active peptic ulceration or active gastro-intestinal (GI) bleeding.
•	Patients who, after taking acetylsalicylic or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors, experience bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions.
•	Pregnancy and lactation (see sections 4.6 and 5.3).
.       Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
•	Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
•	Estimated renal creatinine clearance <30 ml/min.
•	Children and adolescents under 16 years of age.
•	Inflammatory bowel disease.
•	Congestive heart failure (NYHA II-IV).
•	Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Gastrointestinal effects</em></p><p>Upper gastrointestinal complications [perforations, ulcers or bleedings (PUBs)], some of them resulting in fatal outcome, have occurred in patients treated with etoricoxib.</p><p>Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p>There is a further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications) when etoricoxib is taken concomitantly with acetylsalicylic acid (even at low doses). A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid <em>vs</em>. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).</p><p><em>Cardiovascular effects</em></p><p>Clinical trials suggest that the selective COX-2 inhibitor class of drugs may be associated with a risk of thrombotic events (especially myocardial infarction (MI) and stroke), relative to placebo and some NSAIDs. As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).</p><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with etoricoxib after careful consideration (see section 5.1).</p><p>COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of</p><p>antiplatelet effect. Therefore antiplatelet therapies should not be discontinued (see sections above, 4.5 and 5.1.).</p><p><em>Renal effects</em></p><p>Renal prostaglandins may play a compensatory role in the maintenance of renal perfusion. Therefore, under conditions of compromised renal perfusion, administration of etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. Patients at greatest risk of this response are those with pre-existing significantly impaired renal function, uncompensated heart failure, or cirrhosis. Monitoring of renal function in such patients should be considered.</p><p><em>Fluid retention, oedema and hypertension</em></p><p>As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention, oedema and hypertension have been observed in patients taking etoricoxib. All Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including etoricoxib, can be associated with new onset or recurrent congestive heart failure. For information regarding a dose related response for etoricoxib see section 5.1. Caution should be exercised in patients with a history of cardiac failure, left ventricular dysfunction, or hypertension and in patients with pre-existing oedema from any other reason. If there is clinical evidence of deterioration in the condition of these patients, appropriate measures including discontinuation of etoricoxib should be taken.</p><p>Etoricoxib may be associated with more frequent and severe hypertension than some other NSAIDs and selective COX-2 inhibitors, particularly at high doses. Therefore, hypertension should be controlled before treatment with etoricoxib (see section 4.3) and special attention should be paid to blood pressure monitoring during treatment with etoricoxib. Blood pressure should be monitored within two weeks after initiation of treatment and periodically thereafter. If blood pressure rises significantly, alternative treatment should be considered.</p><p><em>Hepatic effects</em></p><p>Elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (approximately three or more times the upper limit of normal) have been&nbsp;</p><p>reported in approximately 1% of patients in clinical trials treated for up to one year with etoricoxib 30, 60 and 90 mg daily.</p><p>Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be monitored. If signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (three times the upper limit of normal) are detected, etoricoxib should be discontinued.</p><p><em>General</em></p><p>If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of etoricoxib therapy should be considered. Medically appropriate supervision should be maintained when using etoricoxib in the elderly and in patients with renal, hepatic, or cardiac dysfunction.</p><p>Caution should be used when initiating treatment with etoricoxib in patients with dehydration. It is advisable to rehydrate patients prior to starting therapy with etoricoxib.</p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs and some selective COX-2 inhibitors during post-marketing surveillance (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy with the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving etoricoxib (see section 4.8). Some selective COX-2 inhibitors have been associated with an increased risk of skin reactions in patients with a history of any drug allergy. Etoricoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>Etoricoxib may mask fever and other signs of inflammation.</p><p>Caution should be exercised when co-administering etoricoxib with warfarin or other oral anticoagulants (see section 4.5).</p><p>The use of etoricoxib, as with any medicinal product known to inhibit cyclooxygenase / prostaglandin synthesis, is not recommended in women attempting to conceive (see sections 4.6, 5.1, and 5.3)<em>.</em></p><p>OZERO tablets contain lactose. Patients with rare hereditary problems ofgalactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacodynamic interactions</em></p><p><em>Oral anticoagulants: </em>In subjects stabilised on chronic warfarin therapy, the administration of etoricoxib 120 mg daily was associated with an approximate 13% increase in prothrombin time International Normalised Ratio (INR). Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with etoricoxib is initiated or the dose of etoricoxib is changed (see section 4.4).</p><p><em>Diuretics, ACE inhibitors and Angiotensin II Antagonists: </em>NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking etoricoxib concomitantly with ACE inhibitors or angiotensin II antagonists.</p><p>Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><em>Acetylsalicylic Acid: </em>In a study in healthy subjects, at steady state, etoricoxib 120 mg once daily had no effect on the anti-platelet activity of acetylsalicylic acid (81 mg once daily). Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular prophylaxis (low-dose acetylsalicylic acid).</p><p>However, concomitant administration of low-dose acetylsalicylic acid with</p><p>etoricoxib may result in an increased rate of GI ulceration or other complications compared to use of etoricoxib alone. Concomitant administration of etoricoxib with doses of acetylsalicylic acid above those for cardiovascular prophylaxis or with other NSAIDs is not recommended (see sections 5.1 and 4.4.).</p><p><em>Ciclosporin and tacrolimus: </em>Although this interaction has not been studied with etoricoxib, coadministration of ciclosporin or tacrolimus with any NSAID may increase the nephrotoxic effect of ciclosporin or tacrolimus. Renal function should be monitored when etoricoxib and either of these drugs is used in combination.</p><p><em>Pharmacokinetic interactions</em></p><p><em>The effect of etoricoxib on the pharmacokinetics of other drugs</em></p><p><em>Lithium: </em>NSAIDs decrease lithium renal excretion and therefore increase lithium plasma levels. If necessary, monitor blood lithium closely and adjust the lithium dosage while the combination is being taken and when the NSAID is withdrawn.</p><p><em>Methotrexate: </em>Two studies investigated the effects of etoricoxib 60, 90 or 120 mg administered once daily for seven days in patients receiving once-weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. Etoricoxib at 60 and 90 mg had no effect on methotrexate plasma concentrations or renal clearance. In one study, etoricoxib 120 mg had no effect, but in the other study, etoricoxib 120 mg increased methotrexate plasma concentrations by 28% and reduced renal clearance of methotrexate by 13%. Adequate monitoring for methotrexate-related toxicity is recommended when etoricoxib and methotrexate are administered concomitantly.</p><p><em>Oral contraceptives: </em>Etoricoxib 60 mg given concomitantly with an oral contraceptive containing 35 micrograms ethinyl estradiol (EE) and 0.5 to 1 mg norethindrone for 21 days increased the steady state AUC<sub>0-24hr</sub> of EE by 37%. Etoricoxib 120 mg given with the same oral contraceptive concomitantly or separated by 12 hours, increased the steady state AUC<sub>0-24hr</sub> of EE by 50 to 60%. This increase in EE concentration should be considered when selecting an oral contraceptive for use with etoricoxib. An increase in EE exposure can increase the incidence of adverse events associated with oral contraceptives (e.g., venous thrombo-embolic events in women at risk).</p><p><em>Hormone Replacement Therapy (HRT):</em></p><p>Administration of etoricoxib 120 mg with hormone replacement therapy consisting of conjugated estrogens (0.625 mg PREMARIN<sup>TM</sup>) for 28 days, increased the mean steady state AUC<sub>0-24hr</sub> of unconjugated estrone (41%), equilin (76%), and 17- &beta;-estradiol (22%). The effect of the recommended chronic doses of etoricoxib (30, 60, and 90 mg) has not been studied. The effects of etoricoxib 120 mg on the exposure (AUC<sub>0-24hr</sub>) to these estrogenic components of PREMARIN were less than half of those observed when PREMARIN was administered alone and the dose was increased from 0.625 to 1.25 mg. The clinical significance of these increases is unknown, and higher doses of PREMARIN were not studied in combination with etoricoxib. These increases in estrogenic concentration should be taken into consideration when selecting post-menopausal hormone therapy for use with etoricoxib because the increase in oestrogen exposure might increase the risk</p><p>of adverse events associated with HRT.</p><p><em>Prednisone/prednisolone: </em>In drug-interaction studies, etoricoxib did not have clinically important effects on the pharmacokinetics of prednisone/prednisolone.</p><p><em>Digoxin: </em>Etoricoxib 120 mg administered once daily for 10 days to healthy volunteers did not alter the steady-state plasma AUC<sub>0-24hr</sub> or renal elimination of digoxin. There was an increase in digoxin C<sub>max</sub> (approximately 33%). This increase is not generally important for most patients. However, patients at high risk of digoxin toxicity should be monitored for this when etoricoxib and digoxin are administered concomitantly.</p><p><em>Effect of etoricoxib on drugs metabolised by sulfotransferases</em></p><p>Etoricoxib is an inhibitor of human sulfotransferase activity, particularly SULT1E1, and has been shown to increase the serum concentrations of ethinyl estradiol. While knowledge about effects of multiple sulfotransferases is presently limited and the clinical consequences for many drugs are still being examined, it may be prudent to exercise care when administering etoricoxib concurrently with other drugs primarily metabolised by human sulfotransferases (e.g., oral salbutamol and minoxidil).</p><p><em>Effect of etoricoxib on drugs metabolised by CYP isoenzymes</em></p><p>Based on <em>in vitro </em>studies, etoricoxib is not expected to inhibit cytochromes P450 (CYP) 1A2, 2C9, 2C19, 2D6, 2E1 or 3A4. In a study in healthy subjects, daily administration of etoricoxib 120 mg did not alter hepatic CYP3A4 activity as assessed by the erythromycin breath test.</p><p><em>Effects of other drugs on the pharmacokinetics of etoricoxib</em></p><p>The main pathway of etoricoxib metabolism is dependent on CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib <em>in vivo</em>. <em>In vitro </em>studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles have not been studied <em>in vivo</em>.</p><p><em>Ketoconazole: </em>Ketoconazole, a potent inhibitor of CYP3A4, dosed at 400 mg once a day for 11 days to healthy volunteers, did not have any clinically important effect on the single-dose pharmacokinetics of 60 mg etoricoxib (43% increase in AUC).</p><p><em>Voriconazole and Miconazole</em>: Co-administration of either oral voriconazole or topical miconazole oral gel, strong CYP3A4 inhibitors, with etoricoxib caused a slight increase in exposure to etoricoxib, but is not considered to be clinically meaningful based on published data.</p><p><em>Rifampicin: </em>Co-administration of etoricoxib with rifampicin, a potent inducer of CYP enzymes, produced a 65% decrease in etoricoxib plasma concentrations. This interaction may result in recurrence of symptoms when etoricoxib is co- administered with rifampicin. While this information may suggest an increase in dose, doses of etoricoxib greater than those listed for each indication have not been studied in combination with rifampicin and are therefore not recommended (see section 4.2).</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_32" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:57.35pt;width:21.15pt;height:16.6pt;z-index:251641856;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>&nbsp;<p><em>Antacids: </em>Antacids do not affect the pharmacokinetics of etoricoxib to a clinically relevant extent.</p></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy category: X Pregnancy&nbsp;</em></p><p>&nbsp;</p><p>No clinical data on exposed pregnancies are available for etoricoxib. Studies in animals have shown reproductive toxicity (see section 5.3). The potential for human risk in pregnancy is unknown. Etoricoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Etoricoxib is contraindicated in pregnancy (see section 4.3). If a woman becomes pregnant during treatment, etoricoxib must be discontinued.</p><p><em>Breastfeeding</em></p><p>It is not known whether etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use etoricoxib must not breast feed (see sections 4.3 and 5.3).</p><p><em>Fertility</em></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_30" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:59.5pt;width:21.15pt;height:16.6pt;z-index:251643904;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody></tbody></table><p>The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_28" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:51.7pt;width:21.15pt;height:16.6pt;z-index:251642880;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAHK9t938DAACdCQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzcVttu2zgQfV9g/4Hgu6NLZMc2qhRx
UhcLpN0gTj9gTFEWUYpUSfrWov++Q1LKte1Du9uHtWF4yBkOZ86cGenV60MryY4bK7QqaXaSUsIV
05VQm5J+uFuOppRYB6oCqRUv6ZFb+vr8zz9ewXxjoGsEI+hB2TmUtHGumyeJZQ1vwZ7ojivU1dq0
4HBpNkllYI+eW5nkaTpJWhCKnj+4ugIHZGvET7iSmn3k1SWoHVh0Kdn88U4fo2S/7hnmavfWdKvu
xvjI2fvdjSGiKikip6BFiGjSK3ozXCbPTm0eHBxq03p7XdfkUNJZVhQpujqWdHw2mc7OxtEdPzjC
UJ9PppN0TAlDgzxLp3naX9f8/WMHrHnzQxcYYgwFhUfh2c4Hp3Yv882RGTHhOx/cQh8Ibg25e3vi
DriLrAo1tt011sgSpS8bUBt+YYzeNxwq6y0iSIhmvCgANtxpva/1/p2uEF3YOh38/SvA3WcN885Y
95brlnihpIYzF+6B3bV1MbzBxENitRTVUkgZFmazvpSG7ECW9Krw3z6jJ2ZSBTC1PxY9xh3ED+/w
Oo9kaIAvsywv0kU+Gy0n07NRsSzGo9lZOh2l2Wwxm6TFrLhafvUBZsW8EVXF1bVQfGjGrHjB9FYw
o62u3QnTbYJ0E4wPDYntmKWxHckeSTjOx7Fm300yDZ9vJdkKxw2Roi3p9N4I5r7Sb1QV+OFAyCgn
T8MPnYIYDP8BFayRZ4CHxx1WgY+eWNXR76zxH9lhNJYM2wYnGQqNNp8p2eN8Kqn9tAXDKZF/KSQa
mrhBMIOwHgRQDI+W1FESxUuHKzyz7YzYNOg5UlnpC2RhLXpaxBh8NNK6lTtKHrIMkXrqtmCugxsU
br3gTW3HFrzupRtnI3dOQ7uHjB+pL+pADjxybxjaPtoFLYo9RgEog9dK7LKScjX6sMIZ/hmDD5Nl
PWTB6xo5HsmNoYMTirhjx2tg2Gd3ouWWvOd7cqtbUJR0oLRFRZrjd5KepuO0wF+OUoFa4VizhFZI
HEwZjgbWgLE8VCWgweE/c465Y74eSndenEz9tI0MilB4xa/jcWEEyCcoLBCFIqDhEclfoHCKsPxG
FPBZZH8LxOQZwFxVN2Dg9puUy/Bh5gvwfyLbQ8JhTmGfe8bdj6St5avuFlsrjvg4s9DCP0qTZy8m
4Wj/IuXffh6vz/8BAAD//wMAUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xpcGJvYXJk
L3RoZW1lL3RoZW1lMS54bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a04w91sxs
0r2h9oiEhCiIA5W4cUBApVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fuxQwdECEp
T3pe/WLNQyTxeUCTsOfdGo8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggYJXIN97xI
qXRtZUX6QMbyIk9JAt+mXMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/EnmZDUIJj
kH5zOqU+Mdhgv64Rci4HTKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0bmT+snHZ
gGC/YWSKcFIIrY9a3UubBX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg1q61XHyJ
f3NJ526/3293M10sUwOyj60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7egCJGk/0l
tA7oaJRxLyBTzrYq4asAX61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTkAMcTQbEW
gNcILn2xJF8ukbQsJH1BU9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJWB714tvP
/nz0MfrjyTcvHn5RjZdl/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaPaUwkukEO
0S6PwTDjFVdzMhGvNmIcYVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87uOgrvRWKm
aIXka1HsALc5Z30uKr1wTcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1dxhOFA5J
QhTS3/g+IRXW3aHU8es29QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNWZfUmOXCR
UBWYVSg/Jsxx41U8UziuYjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9GoaOVRn2
bTaPXaRQdL+K53XMeRm5yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+mxAn36d3g
Fg0dlRYJor/MhI4ltGqnA8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+T8Idb7oD
LgL69vfcTTxLdgik+fLE867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytiemjNyXZpF
soR5IhgBUY8zO0FS7JjSCB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5krfGwyJd
2W1hW28YbD+QWG3zwJKbmpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT6hxphckQ
w2XTgFh4ExYgCJYt4OUO7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfMSQDkTkWM
9CbvFK+VpHU12zeQdpYglcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk573hT2tPAY
pxB1qdd8mIVwGuQrYdP+1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVaktW/0Qa3
npcBNtNfQ4vmKiTDv6YF+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9AZVwNGE6
gn6BczTtbfPJbc5Z0ZVPrwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8nU8pp/D8z
Rc8ncFLQDHQEfDiUFRjpeu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO8jBlDRs+
tUtDJCjMRyoShOxAWzLZdwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1AYM7nn/u
e1ZBk1Avcsr15vSQYu61NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVVAcJKU0E3
K/vXVOEVp1rbsZYsbrRz5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHaQFZfsAsP
pBukJU5g4WSJNpk0K+vabOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46vLe1EV0Nk
j5cokKb5RsYEpurWaRunaBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPgu6UUmGZO
aeaYVk5p5ZR2ToHFWXZfklM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQSwMEFAAG
AAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEu
eG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuy
M3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHK
RH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCM
BjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAA
AAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAy
AQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAHK9t938DAACd
CQAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQIt
ABQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAAAAAAAAAAAAAANwFAABjbGlwYm9hcmQvdGhlbWUv
dGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAOMMAABj
bGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAA
5g0AAAAA
" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>&nbsp;<p>Patients who experience dizziness, vertigo or somnolence while taking etoricoxib should refrain from driving or operating machinery.</p></p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Text_x0020_Box_x0020_27" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:93.1pt;margin-top:9.9pt;width:448.45pt;
  height:16.6pt;z-index:-251655168;visibility:visible;mso-wrap-style:square;
  mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#bfbfbf" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:.35pt;margin-right:0in;margin-bottom:
     0in;margin-left:-.05pt;margin-bottom:.0001pt'><a
     name="4.8_Undesirable_effects"></a><b style='mso-bidi-font-weight:normal'><span
     style='font-size:14.0pt;mso-bidi-font-size:11.0pt'>Undesirable effects<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:178.844px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:177.156px">&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_28" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:51.7pt;width:21.15pt;height:16.6pt;z-index:251642880;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody></tbody></table><p>&nbsp;</p><p>&nbsp;<p>&nbsp;</p></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Text_x0020_Box_x0020_27" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:93.1pt;margin-top:9.9pt;width:448.45pt;
  height:16.6pt;z-index:-251655168;visibility:visible;mso-wrap-style:square;
  mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#bfbfbf" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:.35pt;margin-right:0in;margin-bottom:
     0in;margin-left:-.05pt;margin-bottom:.0001pt'><a
     name="4.8_Undesirable_effects"></a><b style='mso-bidi-font-weight:normal'><span
     style='font-size:14.0pt;mso-bidi-font-size:11.0pt'>Undesirable effects<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><!--[if gte vml 1]></o:wrapblock><![endif]--><p>&nbsp;<p>&nbsp;</p></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile</em></p><p>In clinical trials, etoricoxib was evaluated for safety in 7152 individuals, including 4614 patients with OA, RA, chronic low back pain or ankylosing spondylitis (approximately 600 patients with OA or RA were treated for one year or longer).</p><p>In clinical studies, the undesirable effects profile was similar in patients with OA or RA treated with etoricoxib for one year or longer.</p><p>In a clinical study for acute gouty arthritis, patients were treated with etoricoxib 120 mg once daily for eight days. The adverse experience profile in this study was generally similar to that reported in the combined OA, RA, and chronic low back pain studies.</p><p>In a cardiovascular safety outcomes programme of pooled data from three active comparator controlled trials, 17, 412 patients with OA or RA were treated with etoricoxib (60 mg or 90 mg) for a mean duration of approximately 18 months. The safety data and details from this programme are presented in section 5.1.</p><p>In clinical studies for acute postoperative dental pain following surgery including 614 patients treated with etoricoxib (90 mg or 120 mg), the adverse experience profile in these studies was generally similar to that reported in the combined OA, RA, and chronic low back pain studies.</p><p><em>Tabulated list of adverse reactions</em></p><p>The following undesirable effects were reported at an incidence greater than placebo in clinical trials in patients with OA, RA, chronic low back pain or ankylosing spondylitis treated with etoricoxib 30 mg, 60 mg or 90 mg up to the recommended dose for up to 12 weeks; in the MEDAL Programme studies for up to 3&frac12; years; in short term acute pain studies for up to 7 days; or in post-marketing experience (see Table 1):</p><p>Table 1:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Adverse Reactions</p></td><td style="vertical-align:top"><p>Frequency Category*</p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top"><p>alveolar osteitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>gastroenteritis, upper respiratory infection, urinary tract infection</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p>anaemia (primarily associated with gastrointestinal bleeding), leukopenia, thrombocytopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>hypersensitivity<sup>&Dagger;</sup> <sup>&szlig;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>angioedema/anaphylactic</p><p>/anaphylactoid reactions including shock<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Rare</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>oedema/fluid retention</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>appetite increase or decrease, weight gain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>anxiety, depression, mental acuity decreased, hallucinations<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>confusion<sup>&Dagger;</sup><em>, </em>restlessness<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>dizziness, headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dysgeusia, insomnia, paresthaesia/hypaesthesia, somnolence</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>blurred vision, conjunctivitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td><td style="vertical-align:top"><p>tinnitus, vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders</em></p></td><td style="vertical-align:top"><p>palpitations, arrhythmia<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>atrial fibrillation, tachycardia<sup>&Dagger;</sup><em>, </em>congestive heart failure, non- specific ECG changes, angina pectoris<sup>&Dagger;</sup>, myocardial infarction<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>flushing, cerebrovascular accident<sup>&sect;</sup>, transient ischaemic attack, hypertensive crisis<sup>&Dagger;</sup><em>, </em>vasculitis<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>bronchospasm<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cough, dyspnoea, epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal distention, bowel movement pattern change, dry mouth, gastroduodenal ulcer, peptic ulcers including gastrointestinal perforation and bleeding, irritable bowel syndrome, pancreatitis<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top"><p>ALT increased, AST increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatitis<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic failure<sup>&Dagger;</sup>, jaundice<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Rare<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>ecchymosis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>facial oedema, pruritus, rash, erythema<sup>&Dagger;</sup>, urticaria<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>&Dagger;</sup>, toxic epidermal necrolysis<sup>&Dagger;</sup>, fixed drug eruption<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Rare<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>muscular cramp/spasm, musculoskeletal pain/stiffness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>proteinuria, serum creatinine</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased, renal failure/renal insufficiency<sup>&Dagger;</sup>(see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>asthenia/fatigue, flu-like disease</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>chest pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Investigations</em></p></td><td style="vertical-align:top"><p>blood urea nitrogen increased, creatine phosphokinase increased, hyperkalaemia, uric acid increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blood sodium decreased</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to&lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare(&lt;1/10,000).</p><p>&Dagger; This adverse reaction was identified through post-marketing surveillance. Its reported frequency has been estimated based upon the highest frequency observed across clinical trial data pooled by indication and approved dose.</p><p>&dagger;The frequency category of &ldquo;Rare&rdquo; was defined per the Summary of Product Characteristics (SmPC) guidance (rev. 2, Sept 2009) on the basis of an estimated upper bound of the 95% confidence interval for 0 events given the number of subjects treated with OZERO in the analysis of the Phase III data pooled by dose and indication (n=15,470).</p><p>&szlig; Hypersensitivity includes the terms &quot;allergy&quot;, &quot;drug allergy&quot;, &quot;drug hypersensitivity&quot;, &quot;hypersensitivity&quot;, &quot;hypersensitivity NOS&quot;, &quot;hypersensitivity reaction&quot; and &quot;nonspecific allergy&quot;.</p><p>&sect;Based on analyses of long-term placebo and active controlled clinical trials, selective COX-2 inhibitors have been associated with an increased risk of serious thrombotic arterial events, including myocardial infarction and stroke. The absolute risk increase for such events is unlikely to exceed 1% per year based on existing data (uncommon).</p></td></tr></tbody></table><p>The following serious undesirable effects have been reported in association with the use of NSAIDs and cannot be ruled out for etoricoxib: nephrotoxicity including interstitial nephritis and nephrotic syndrome.</p><p>Description of selected adverse reactions: NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_23" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:-23.9pt;width:21.15pt;height:16.6pt;z-index:251645952;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>&nbsp;</strong></p></td></tr></tbody></table></td></tr></tbody></table><p>In clinical studies, administration of single doses of etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. There have been reports of acute overdosage with etoricoxib, although adverse experiences were not reported in the majority of cases. The most frequently observed adverse experiences were consistent with the safety profile for etoricoxib (e.g. gastrointestinal events, cardiorenal events).</p><p>&nbsp;</p><p>In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the GI tract, employ clinical monitoring, and institute supportive therapy, if required.</p><p><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_22" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:1in;margin-top:57.4pt;
 width:14.05pt;height:16.6pt;z-index:251644928;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAdbSsKnwDAACcCQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzcVttu2zgQfV9g/4Hgu6NLZMc2qhRx
UhcLpN0gTj9gTFEWUYpUSfrWov++Q1LKte1Du9uHtWF4SA4PZw7PjPTq9aGVZMeNFVqVNDtJKeGK
6UqoTUk/3C1HU0qsA1WB1IqX9MgtfX3+5x+vYL4x0DWCEURQdg4lbZzr5kliWcNbsCe64wrXam1a
cDg0m6QysEfkViZ5mk6SFoSi5w9QV+CAbI34CSip2UdeXYLagUVIyeaPZ/oYJft1ZJir3VvTrbob
4yNn73c3hoiqpMicghYpokm/0LvhMHm2a/MAcKhN6/11XZNDSWdZUaQIdSzpZJYWp+NxhOMHRxiu
Z2dTnKSEoUOepdM87Y9r/v4xAGve/BACQ4yhoPEoPNv54NTuZb55PiR854Nb6APBqSF370/cAWcx
5nDHtrvGO7JE6csG1IZfGKP3DYfKeo9IErIZDwqEDWdaj7Xev9MVsgtbpwPev0LcfdYw74x1b7lu
iTdKajhz4RzYXVsXwxtcPCVWS1EthZRhYDbrS2nIDmRJrwr/7TN64iZVIFP7bRExziB/eIZf80yG
Avgyy/IiXeSz0XIyPRsVy2I8mp2l01GazRazSVrMiqvlVx9gVswbUVVcXQvFh2LMihdKbwUz2ura
nTDdJig3wfhQkFiOWRrLkexRhON8HO/su0mm4fOtJFvhuCFStCWd3jvB3N/0G1UFfTgQMtrJ0/BD
pSAHw39gBe/IK8DT4w6roEcvrOroZ9b4j+owGq8MywY7GRqNNp8p2WN/Kqn9tAXDKZF/KRQaurjB
MIOxHgxQDLeW1FESzUuHI9yz7YzYNIgcpaz0BaqwFr0sYgw+Gmndyh0lD1mGSL10WzDXAQaNW294
V9uxBa9768bZqB0s7SiMJ8sXdRAHzt07hrIPzLCwimbPUSDK4LESq6ykXI0+rLCHf8bgQ2dZD1nw
ukaNR3Fj6OCEIu7Y8RoY1tmdaLkl7/me3OoWFCUdKG1xIc3xO0lP03Fa4C9Hq8BV4VizhFZIbEwZ
PjRYA8bycCuBDQ7/GTjmjvl6Kt35+MQ32yigyISf/3U6LowA+YSEBZJQBDI8IfkLEk6Rld9IAj6K
7G9hmDwjmKvqBgzcflNxGT7L/AX8n7T2kHBoU1jmXnH3HWlr+aq7xcqKhRxbFnr4J2ny7L0kbO3f
o/zLz+Px+T8AAAD//wMAUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xpcGJvYXJkL3Ro
ZW1lL3RoZW1lMS54bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a04w91sxs0r2h
9oiEhCiIA5W4cUBApVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fuxQwdECEpT3pe
/WLNQyTxeUCTsOfdGo8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggYJXIN97xIqXRt
ZUX6QMbyIk9JAt+mXMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/EnmZDUIJjkH5z
OqU+Mdhgv64Rci4HTKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0bmT+snHZgGC/
YWSKcFIIrY9a3UubBX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg1q61XHyJf3NJ
526/3293M10sUwOyj60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7egCJGk/0ltA7o
aJRxLyBTzrYq4asAX61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTkAMcTQbEWgNcI
Ln2xJF8ukbQsJH1BU9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJWB714tvP/nz0
MfrjyTcvHn5RjZdl/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaPaUwkukEO0S6P
wTDjFVdzMhGvNmIcYVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87uOgrvRWKmaIXk
a1HsALc5Z30uKr1wTcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1dxhOFA5JQhTS
3/g+IRXW3aHU8es29QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNWZfUmOXCRUBWY
VSg/Jsxx41U8UziuYjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9GoaOVRn2bTaP
XaRQdL+K53XMeRm5yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+mxAn36d3gFg0d
lRYJor/MhI4ltGqnA8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+T8Idb7oDLgL6
9vfcTTxLdgik+fLE867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytiemjNyXZpFsoR5
IhgBUY8zO0FS7JjSCB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5krfGwyJd2W1h
W28YbD+QWG3zwJKbmpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT6hxphckQw2XT
gFh4ExYgCJYt4OUO7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfMSQDkTkWM9Cbv
FK+VpHU12zeQdpYglcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk573hT2tPAYpxB1
qdd8mIVwGuQrYdP+1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVaktW/0Qa3npcB
NtNfQ4vmKiTDv6YF+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9AZVwNGE6gn6B
czTtbfPJbc5Z0ZVPrwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8nU8pp/D8zRc8n
cFLQDHQEfDiUFRjpeu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO8jBlDRs+tUtD
JCjMRyoShOxAWzLZdwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1AYM7nn/ue1ZB
k1Avcsr15vSQYu61NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVVAcJKU0E3K/vX
VOEVp1rbsZYsbrRz5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHaQFZfsAsPpBuk
JU5g4WSJNpk0K+vabOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46vLe1EV0Nkj5co
kKb5RsYEpurWaRunaBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPgu6UUmGZOaeaY
Vk5p5ZR2ToHFWXZfklM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQSwMEFAAGAAgA
AAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1s
LnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuyM3li
TJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1A
VzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCMBjMH
SldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAA
CwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAdbSsKnwDAACcCQAA
HwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQA
BgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAAAAAAAAAAAAAANkFAABjbGlwYm9hcmQvdGhlbWUvdGhl
bWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAOAMAABjbGlw
Ym9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAA4w0A
AAAA
" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody></tbody></table><p>Etoricoxib is not dialysable by haemodialysis; it is not known whether etoricoxib is dialysable by peritoneal dialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non- steroids, coxibs, </em>ATC code: MO1 AH05</p><p>Mechanism of Action</p><p>Etoricoxib is an oral, selective cyclo-oxygenase-2 (COX-2) inhibitor within the clinical dose range.</p><p>Across clinical pharmacology studies, OZERO produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily. Etoricoxib did not inhibit gastric prostaglandin synthesis and had no effect on platelet function.</p><p>Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.</p><p>Clinical efficacy and safety Efficacy</p><p>In patients with osteoarthritis (OA), etoricoxib 60 mg once daily provided significant improvements in pain and patient assessments of disease status. These beneficial effects were observed as early as the second day of therapy and maintained for up to 52 weeks. Studies with etoricoxib 30 mg once daily demonstrated efficacy superior to placebo over a 12 week treatment period (using similar assessments as the above studies). In a dose ranging study, etoricoxib 60 mg demonstrated significantly greater improvement than 30 mg for all 3 primary endpoints over 6 weeks of treatment. The 30 mg dose has not been studied in osteoarthritis of hands.</p><p>In patients with rheumatoid arthritis (RA), etoricoxib 90 mg once daily provided significant improvements in pain, inflammation, and mobility. These beneficial effects were maintained over the 12-week treatment periods.</p><p>In patients experiencing attacks of acute gouty arthritis, etoricoxib 120 mg once daily over an eight-day treatment period, relieved moderate to extreme joint pain</p><p>and inflammation comparable to indomethacin 50 mg three times daily. Pain relief was observed as early as four hours after initiation of treatment.</p><p>In patients with ankylosing spondylitis, etoricoxib 90 mg once daily provided significant improvements in spine pain, inflammation, stiffness and function. The clinical benefit of etoricoxib was observed as early as the second day of therapy after initiation of treatment and was maintained throughout the 52-week treatment period.</p><p>In a clinical study evaluating postoperative dental pain, etoricoxib 90 mg was administered once daily for up to three days. In the subgroup of patients with moderate pain at baseline, etoricoxib 90 mg demonstrated a similar analgesic effect to that of ibuprofen 600 mg (16.11 vs. 16.39; P=0.722), and greater than that of paracetamol/codeine 600 mg/60 mg (11.00; P&lt;0.001) and placebo (6.84; P&lt;0.001) as measured by total pain relief over the first 6 hours (TOPAR6). The proportion of patients reporting rescue medication usage within the first 24 hours of dosing was 40.8% for etoricoxib 90 mg, 25.5% for ibuprofen 600 mg Q6h, and 46.7% for paracetamol/codeine 600 mg/60 mg Q6h compared to 76.2% for placebo. In this study, the median onset of action (perceptible pain relief) of 90 mg etoricoxib was 28 minutes after dosing.</p><p>Safety</p><p>Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Programme</p><p>The MEDAL Programme was a prospectively designed Cardiovascular (CV) Safety Outcomes Programme of pooled data from three randomized, double-blind active comparator controlled trials, the MEDAL study, EDGE II and EDGE.</p><p>The MEDAL Study, was an endpoint driven CV Outcomes study in 17,804 OA and 5,700 RA patients treated with etoricoxib 60 (OA) or 90 mg (OA and RA) or diclofenac 150 mg daily for a mean period of 20.3 months (maximum of 42.3 months, median 21.3 months). In this trial, only serious adverse events and discontinuations due to any adverse events were recorded.</p><p>The EDGE and EDGE II studies compared the gastrointestinal tolerability of etoricoxib versus diclofenac. The EDGE study included 7111 OA patients treated</p><p>with a dose of etoricoxib 90 mg daily (1.5 times the dose recommended for OA) or diclofenac 150 mg daily for a mean period of 9.1 months (maximum 16.6 months, median 11.4 months). The EDGE II study included 4086 RA patients treated with etoricoxib 90 mg daily or diclofenac 150 mg daily for a mean period of 19.2 months (maximum 33.1 months, median 24 months).</p><p>In the pooled MEDAL Programme, 34,701 patients with OA or RA were treated for a mean duration of 17.9 months (maximum 42.3 months, median 16.3 months) with approximately 12,800 patients receiving treatment for more than 24 months. Patients enrolled in the Programme had a wide range of cardiovascular and gastrointestinal risk factors at baseline. Patients with a recent history of myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention within 6 months preceding enrollment were excluded. Use of gastroprotective agents and low dose aspirin were permitted in the studies.</p><p>Overall Safety:</p><p>There was no significant difference between etoricoxib and diclofenac in the rate of cardiovascular thrombotic events. Cardiorenal adverse events were observed more frequently with etoricoxib than with diclofenac, and this effect was dose- dependent (see specific results below). Gastrointestinal and hepatic adverse events were observed significantly more frequently with diclofenac than etoricoxib. The incidence of adverse experiences in EDGE and EDGE II and of adverse experiences considered serious or resulting in discontinuation in the MEDAL study was higher with etoricoxib than diclofenac.</p><p>Cardiovascular safety results:</p><p>The rate of confirmed thrombotic cardiovascular serious adverse events (consisting of cardiac, cerebrovascular, and peripheral vascular events) was comparable between etoricoxib and diclofenac, and data are summarized in the table below.</p><p>There were no statistically significant differences in thrombotic event rates between etoricoxib and diclofenac across all subgroups analyzed including patient categories across a range of baseline cardiovascular risk. When considered separately, the relative risks for confirmed thrombotic cardiovascular serious adverse events with etoricoxib 60 mg or 90 mg compared with diclofenac 150mg were similar.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 2: Rates of Confirmed Thrombotic CV Events (Pooled MEDAL Programme)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Etoricoxib (N=16819)</p><p>25836 Patient-Years</p></td><td style="vertical-align:top"><p>Diclofenac (N=16483)</p><p>24766 Patient-Years</p></td><td style="vertical-align:top"><p>Between Treatment Comparison</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rate<sup>&dagger;</sup> (95% CI)</p></td><td style="vertical-align:top"><p>Rate<sup>&dagger;</sup> (95% CI)</p></td><td style="vertical-align:top"><p>Relative Risk (95% CI)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Confirmed Thrombotic Cardiovascular Serious Adverse Events</p></td></tr><tr><td style="vertical-align:top"><p>Per-protocol</p></td><td style="vertical-align:top"><p>1.24 (1.11, 1.38)</p></td><td style="vertical-align:top"><p>1.30 (1.17, 1.45)</p></td><td style="vertical-align:top"><p>0.95 (0.81, 1.11)</p></td></tr><tr><td style="vertical-align:top"><p>Intent-to-treat</p></td><td style="vertical-align:top"><p>1.25 (1.14, 1.36)</p></td><td style="vertical-align:top"><p>1.19 (1.08, 1.30)</p></td><td style="vertical-align:top"><p>1.05 (0.93, 1.19)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Confirmed Cardiac Events</p></td></tr><tr><td style="vertical-align:top"><p>Per-protocol</p></td><td style="vertical-align:top"><p>0.71 (0.61, 0.82)</p></td><td style="vertical-align:top"><p>0.78 (0.68, 0.90)</p></td><td style="vertical-align:top"><p>0.90 (0.74, 1.10)</p></td></tr><tr><td style="vertical-align:top"><p>Intent-to-treat</p></td><td style="vertical-align:top"><p>0.69 (0.61, 0.78)</p></td><td style="vertical-align:top"><p>0.70 (0.62, 0.79)</p></td><td style="vertical-align:top"><p>0.99 (0.84, 1.17)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Confirmed Cerebrovascular Events</p></td></tr><tr><td style="vertical-align:top"><p>Per-protocol</p></td><td style="vertical-align:top"><p>0.34 (0.28, 0.42)</p></td><td style="vertical-align:top"><p>0.32 (0.25, 0.40)</p></td><td style="vertical-align:top"><p>1.08 (0.80, 1.46)</p></td></tr><tr><td style="vertical-align:top"><p>Intent-to-treat</p></td><td style="vertical-align:top"><p>0.33 (0.28, 0.39)</p></td><td style="vertical-align:top"><p>0.29 (0.24, 0.35)</p></td><td style="vertical-align:top"><p>1.12 (0.87, 1.44)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Confirmed Peripheral Vascular Events</p></td></tr><tr><td style="vertical-align:top"><p>Per-protocol</p></td><td style="vertical-align:top"><p>0.20 (0.15, 0.27)</p></td><td style="vertical-align:top"><p>0.22 (0.17, 0.29)</p></td><td style="vertical-align:top"><p>0.92 (0.63, 1.35)</p></td></tr><tr><td style="vertical-align:top"><p>Intent-to-treat</p></td><td style="vertical-align:top"><p>0.24 (0.20, 0.30)</p></td><td style="vertical-align:top"><p>0.23 (0.18, 0.28)</p></td><td style="vertical-align:top"><p>1.08 (0.81, 1.44)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&dagger;Events per 100 Patient-Years; CI=confidence interval</p><p>N=total number of patients included in Per-protocol population</p><p>Per-protocol: all events on study therapy or within 14 days of discontinuation (excluded:</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_20" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:518.4pt;height:116.4pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".72pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.85pt;margin-right:3.95pt;
    margin-bottom:0in;margin-left:1.15pt;margin-bottom:.0001pt;line-height:
    115%'>patients who took &lt; 75% of their study medication or took
    non-study NSAIDs &gt;10% of the time).<o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:10.0pt;margin-right:11.3pt;
    margin-bottom:0in;margin-left:1.15pt;margin-bottom:.0001pt;line-height:
    115%'>Intent-to-treat: all confirmed events up to the end of the trial
    (included patients potentially exposed to non-study interventions following
    discontinuation of study medication). Total number of patients randomised,
    n= 17412 on etoricoxib and 17289 on diclofenac.<o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="697" height="162" alt="Text Box: patients who took &lt; 75% of their study medication or took non-study NSAIDs &gt;10% of the time).
Intent-to-treat: all confirmed events up to the end of the trial (included patients potentially exposed to non-study interventions following discontinuation of study medication). Total number of patients randomised, n= 17412 on etoricoxib and 17289 on diclofenac.
" src="file:///C:/Users/mariam/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:518.4pt;height:116.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>CV mortality, as well as overall mortality, was similar between the etoricoxib and</p><p>diclofenac treatment groups. Cardiorenal Events:</p><p>Approximately 50% of patients enrolled in the MEDAL study had a history of hypertension at baseline. In the study, the incidence of discontinuations due to hypertension-related adverse events was statistically significantly higher for etoricoxib than for diclofenac. The incidence of congestive heart failure adverse events (discontinuations and serious events) occurred at similar rates on etoricoxib 60 mg compared to diclofenac 150 mg but was higher for etoricoxib 90 mg compared to diclofenac 150 mg (statistically significant for 90 mg etoricoxib vs.</p><p>150 mg diclofenac in MEDAL OA cohort). The incidence of confirmed congestive heart failure adverse events (events that were serious and resulted in hospitalisation or a visit to an emergency department) was non-significantly higher with etoricoxib than diclofenac 150 mg, and this effect was dose-dependent. The incidence of discontinuations due to edema-related adverse events was higher for etoricoxib than diclofenac 150 mg, and this effect was dose-dependent (statistically significant for etoricoxib 90 mg, but not for etoricoxib 60 mg).</p><p>The cardiorenal results for EDGE and EDGE II were consistent with those described for the MEDAL Study.</p><p>In the individual MEDAL Programme studies, for etoricoxib (60 mg or 90 mg), the absolute incidence of discontinuation in any treatment group was up to 2.6% for hypertension, up to 1.9% for oedema, and up to 1.1% for congestive heart failure, with higher rates of discontinuation observed with etoricoxib 90 mg than etoricoxib 60 mg.</p><p>MEDAL Programme Gastrointestinal Tolerability Results:</p><p>A significantly lower rate of discontinuations of treatment for any clinical (e.g., dyspepsia, abdominal pain, ulcer) GI adverse event was observed with etoricoxib compared with diclofenac within each of the three component studies of the MEDAL Programme. The rates of discontinuations due to adverse clinical GI events per hundred patient-years over the entire period of study were as follows:</p><p>3.23 for etoricoxib and 4.96 for diclofenac in the MEDAL Study; 9.12 with etoricoxib and 12.28 with diclofenac in the EDGE study; and 3.71 with etoricoxib and 4.81 with diclofenac in the EDGE II study.</p><p>MEDAL Programme Gastrointestinal Safety Results:</p><p>Overall upper GI events were defined as perforations, ulcers and bleeds. The subset of overall upper GI events considered complicated included perforations, obstructions, and complicated bleeding; the subset of upper GI events considered uncomplicated included uncomplicated bleeds and uncomplicated ulcers. A significantly lower rate of overall upper GI events was observed with etoricoxib compared to diclofenac. There was no significant difference between etoricoxib and diclofenac in the rate of complicated events. For the subset of upper GI haemorrhage events (complicated and uncomplicated combined), there was no significant difference between etoricoxib and diclofenac. The upper GI benefit for etoricoxib compared with diclofenac was not statistically significant in patients taking concomitant low-dose aspirin (approximately 33% of patients).</p><p>The rates per hundred patient-years of confirmed complicated and uncomplicated upper GI clinical events (perforations, ulcers and bleeds (PUBs)) were 0.67 (95% CI 0.57, 0.77) with etoricoxib and 0.97 (95% CI 0.85, 1.10) with diclofenac,</p><p>yielding a relative risk of 0.69 (95% CI 0.57, 0.83).</p><p>The rate for confirmed upper GI events in elderly patients was evaluated and the largest reduction was observed in patients &ge; 75 years of age (1.35 [95% CI 0.94, 1.87] vs. 2.78 [95% CI 2.14, 3.56] events per hundred patient-years for etoricoxib and diclofenac, respectively.</p><p>The rates of confirmed lower GI clinical events (small or large bowel perforation, obstruction, or haemorrhage, (POBs)) were not significantly different between etoricoxib and diclofenac.</p><p>MEDAL Programme Hepatic Safety Results:</p><p>Etoricoxib was associated with a statistically significantly lower rate of discontinuations due to hepatic-related adverse experiences than diclofenac. In the pooled MEDAL Programme, 0.3% of patients on etoricoxib and 2.7% of patients on diclofenac discontinued due to hepatic-related adverse experiences. The rate per hundred patient-years was 0.22 on etoricoxib and 1.84 for diclofenac (p-value was</p><p>&lt;0.001 for etoricoxib vs. diclofenac). However, most hepatic adverse experiences in the MEDAL Programme were non-serious.</p><p>Additional Thrombotic Cardiovascular Safety Data</p><p>In clinical studies excluding the MEDAL Programme Studies, approximately 3100 patients were treated with etoricoxib &ge;60 mg daily for 12 weeks or longer. There was no discernible difference in the rate of confirmed serious thrombotic cardiovascular events between patients receiving etoricoxib &ge;60 mg, placebo, or non-naproxen NSAIDs. However, the rate of these events was higher in patients receiving etoricoxib compared with those receiving naproxen 500 mg twice daily. The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and selective COX-2 inhibitors may be of clinical significance in patients at risk of thrombo-embolic events. Selective COX-2 inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane. The clinical relevance of these observations has not been established.</p><p>Additional Gastrointestinal Safety Data</p><p>In two 12-week double-blind endoscopy studies, the cumulative incidence of gastroduodenal ulceration was significantly lower in patients treated with etoricoxib 120 mg once daily than in patients treated with either naproxen 500 mg twice daily or ibuprofen 800 mg three times daily. Etoricoxib had a higher incidence of ulceration as compared to placebo.</p><p>Renal Function Study in the Elderly</p><p>A randomized, double-blind, placebo-controlled, parallel-group study evaluated the effects of 15 days of treatment of etoricoxib (90 mg), celecoxib (200 mg bid), naproxen (500 mg bid) and placebo on urinary sodium excretion, blood pressure,</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_19" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1in;margin-top:162.85pt;width:21.15pt;height:16.6pt;z-index:251646976;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody></tbody></table><p>and other renal function parameters in subjects 60 to 85 years of age on a 200- mEq/day sodium diet. Etoricoxib, celecoxib, and naproxen had similar effects on urinary sodium excretion over the 2 weeks of treatment. All active comparators showed an increase relative to placebo with respect to systolic blood pressures; however, etoricoxib was associated with a statistically significant increase at Day 14 when compared to celecoxib and naproxen (mean change from baseline for systolic blood pressure: etoricoxib 7.7 mmHg, celecoxib 2.4 mmHg, naproxen 3.6 mmHg).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Orally administered etoricoxib is well absorbed. The absolute bioavailability is approximately 100%. Following 120 mg once-daily dosing to steady state, the peak plasma concentration (geometric mean C<sub>max</sub> = 3.6 &micro;g/ml) was observed at approximately 1 hour (T<sub>max</sub>) after administration to fasted adults. The geometric mean area under the curve (AUC<sub>0-24hr</sub>) was 37.8 &micro;g&bull;hr/ml. The pharmacokinetics of etoricoxib are linear across the clinical dose range.</p><p>Dosing with food (a high-fat meal) had no effect on the extent of absorption of etoricoxib after administration of a 120-mg dose. The rate of absorption was affected, resulting in a 36% decrease in C<sub>max</sub> and an increase in T<sub>max</sub> by 2 hours. These data are not considered clinically significant. In clinical trials, etoricoxib was administered without regard to food intake.</p><p><em>Distribution</em></p><p>Etoricoxib is approximately 92% bound to human plasma protein over the range of concentrations of 0.05 to 5 &micro;g/ml. The volume of distribution at steady state (V<sub>dss</sub>) was approximately 120 l in humans.</p><p>Etoricoxib crosses the placenta in rats and rabbits, and the blood-brain barrier in rats.</p><p><em>Biotransformation</em></p><p>Etoricoxib is extensively metabolised with &lt;1% of a dose recovered in urine as the parent drug. The major route of metabolism to form the 6&#39;-hydroxymethyl</p><p>&nbsp;</p><p>&nbsp;</p><p>derivative is catalyzed by CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib <em>in vivo</em>. <em>In vitro </em>studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles <em>in vivo </em>have not been studied.</p><p>Five metabolites have been identified in man. The principal metabolite is the 6&#39;- carboxylic acid derivative of etoricoxib formed by further oxidation of the 6&#39;- hydroxymethyl derivative. These principal metabolites either demonstrate no measurable activity or are only weakly active as COX-2 inhibitors. None of these metabolites inhibit COX-1.</p><p><em>Elimination</em></p><p>Following administration of a single 25-mg radiolabeled intravenous dose of etoricoxib to healthy subjects, 70% of radioactivity was recovered in urine and 20% in faeces, mostly as metabolites. Less than 2% was recovered as unchanged drug.</p><p>Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal excretion. Steady state concentrations of etoricoxib are reached within seven days of once daily administration of 120 mg, with an accumulation ratio of approximately 2, corresponding to a half-life of approximately 22 hours. The plasma clearance after a 25-mg intravenous dose is estimated to be approximately 50 ml/min.</p><p><em>Characteristics in patients</em></p><p><em>Elderly patients: </em>Pharmacokinetics in the elderly (65 years of age and older) are similar to those in the young.</p><p><em>Gender: </em>The pharmacokinetics of etoricoxib are similar between men and women.</p><p><em>Hepatic impairment: </em>Patients with mild hepatic dysfunction (Child-Pugh score 5-</p><p>6) administered etoricoxib 60 mg once daily had an approximately 16% higher mean AUC as compared to healthy subjects given the same regimen. Patients with moderate hepatic dysfunction (Child-Pugh score 7-9) administered etoricoxib 60 mg <em>every other day </em>had similar mean AUC to the healthy subjects given etoricoxib 60 mg once daily; etoricoxib 30 mg once daily has not been studied in this&nbsp;</p><p>population. There are no clinical or pharmacokinetic data in patients with severe hepatic dysfunction (Child-Pugh score &ge;10). (See sections 4.2 and 4.3.)</p><p><em>Renal impairment: </em>The pharmacokinetics of a single dose of etoricoxib 120 mg in patients with moderate to severe renal insufficiency and patients with end-stage renal disease on haemodialysis were not significantly different from those in healthy subjects. Haemodialysis contributed negligibly to elimination (dialysis clearance approximately 50 ml/min). (See sections 4.3 and 4.4.)</p><p><em>Paediatric patients: </em>The pharmacokinetics of etoricoxib in paediatric patients (&lt;12 years old) have not been studied.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
 path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_17" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:1in;margin-top:131.1pt;
 width:21.15pt;height:16.6pt;z-index:251648000;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#d4d4d4" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>&nbsp;<p>In a pharmacokinetic study (n=16) conducted in adolescents (aged 12 to 17) the pharmacokinetics in adolescents weighing 40 to 60 kg given etoricoxib 60 mg once daily and adolescents &gt;60 kg given etoricoxib 90 mg once daily were similar to the pharmacokinetics in adults given etoricoxib 90 mg once daily. Safety and effectiveness of etoricoxib in paediatric patients have not been established (see</p></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>In preclinical studies, etoricoxib has been demonstrated not to be genotoxic. Etoricoxib was not carcinogenic in mice. Rats developed hepatocellular and thyroid follicular cell adenomas at &gt;2-times the daily human dose [90 mg] based on systemic exposure when dosed daily for approximately two years.</p><p>Hepatocellular and thyroid follicular cell adenomas observed in rats are considered to be a consequence of rat-specific mechanism related to hepatic CYP enzyme induction. Etoricoxib has not been shown to cause hepatic CYP3A enzyme induction in humans.</p><p>In the rat, gastrointestinal toxicity of etoricoxib increased with dose and exposure time. In the 14-week toxicity study etoricoxib caused gastrointestinal ulcers at exposures greater than those seen in man at the therapeutic dose. In the 53- and 106-week toxicity study, gastrointestinal ulcers were also seen at exposures comparable to those seen in man at the therapeutic dose. In dogs, renal and gastrointestinal abnormalities were seen at high exposures.</p><p>Etoricoxib was not teratogenic in reproductive toxicity studies conducted in rats at 15 mg/kg/day (this represents approximately 1.5 times the daily human dose [90 mg] based on systemic exposure). In rabbits, a treatment related increase in cardiovascular malformations was observed at exposure levels below the clinical exposure at the daily human dose (90mg). However no treatment-related external or skeletal foetal malformations were observed. In rats and rabbits, there was a dose dependent increase in post implantation loss at exposures greater than or equal to 1.5 times the human exposure (see sections 4.3 and 4.6).</p><p>Etoricoxib is excreted in the milk of lactating rats at concentrations approximately two-fold those in plasma. There was a decrease in pup body weight following exposure of pups to milk from dams administered etoricoxib during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Calcium hydrogen phosphate anhydrous, Microcrystalline cellulose (Avicel PH 112), Croscarmellose sod, Colloidal silicon dioxide (Aerosil200), Magnesium Stearate, Opadry II green or Opadry II White</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_10" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:70.55pt;
  margin-top:13.05pt;width:471pt;height:18.6pt;z-index:-251643904;visibility:visible;
  mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#bfbfbf" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:1.4pt;line-height:15.85pt;
     mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
     style='font-size:14.0pt;mso-bidi-font-size:11.0pt'>6.5 Nature and contents
     of container<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OZERO 60 mg is provided in Alu/Alu blister Packs contains 30 film coated tablet</p><p>&nbsp;</p><p>OZERO 90 mg is provided in Alu/Alu blister&nbsp;</p><p>Packs contains 30 film coated tablet</p><p>&nbsp;</p><p>OZERO 120 mg is provided in Alu/Alu blister Packs contains 7 film coated tablet</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                    Pharco International pharmaceutical company- Al Madina Almonawara, Saudi Arabia
   For more information, please contact
Pharco International pharmaceutical company- Al Madina Almonawara, Saudi Arabia
Tel: +966 112349763

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                    October 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>